You have 9 free searches left this month | to do more

dasatinib

Dasatinib is a drug used to treat Chronic Myeloid Leukemia, Acute Lymphoblastic Leukemia, Leukemia, and other conditions. Dasatinib is being actively studied in 66 studies and prior, has been studied in 110.

Top SponsorsTop SitesTop Investigators
Bristol-Myers SquibbLocal InstitutionStephen Spurgeon
National Cancer Institute (NCI)M D Anderson Cancer CenterAbhinav Deol
M.D. Anderson Cancer CenterCity of Hope Comprehensive Cancer CenterPhilip C. Amrein, M.D.
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
J
Dasatinib In Waldenström Macroglobulinemia
Recruiting
  • Waldenstrom Macroglobulinemia
  • DASATINIB
  • Dasatinib
  • Boston, Massachusetts
    Dana Farber Cancer Institute
2021-11-15
Nov 15, 2021
S
Dose Reduced Dasatinib (70 mg Daily) as First-line Treatment for Newly Diagnosed CML-CP
Recruiting
  • Dasatinib
  • +2 more
  • Dasatinib
  • Shenzhen, Guangdong, China
    Xin Du
2021-06-09
Jun 9, 2021
M
Dasatinib in Treating Patients With Early Chronic Phase Chronic Myelogenous Leukemia
Active, not recruiting
  • Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
  • Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia
  • Dasatinib
  • +4 more
  • Houston, Texas
    M D Anderson Cancer Center
2021-05-05
May 5, 2021
M
Dasatinib and Venetoclax in Treating Patients With Philadelphia Chromosome Positive or BCR-ABL1 Positive Early Chronic Phase Chronic Myelogenous Leukemia
Recruiting
  • Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
  • Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia
  • Dasatinib
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
2021-05-07
May 7, 2021
B
Continuing Treatment for Subjects Who Have Participated on a Prior Protocol Investigating Dasatinib
Active, not recruiting
  • Multiple Indications Cancer
  • Dasatinib
  • Besancon, France
  • +5 more
2021-12-02
Dec 2, 2021
M
ASTX727 and Dasatinib for the Treatment of Newly Diagnosed Philadelphia Chromosome or BCR-ABL Positive Chronic Myeloid Leukemia in Chronic Phase
Recruiting
  • Chronic Phase Chronic Myelogenous Leukemia
  • +3 more
  • Dasatinib
  • Decitabine and Cedazuridine
  • Houston, Texas
    M D Anderson Cancer Center
2021-12-29
Dec 29, 2021
O
Dasatinib in Treating Patients With Chronic Lymphocytic Leukemia - 2018
Completed
Has Results
  • Refractory Chronic Lymphocytic Leukemia
  • +4 more
  • Dasatinib
  • +2 more
  • Portland, Oregon
    OHSU Knight Cancer Institute
2021-03-15
Mar 15, 2021
N
Dasatinib in Combination With Bevacizumab to Treat Advanced Solid Tumors - 2018
Completed
  • Solid Tumors
  • Bethesda, Maryland
    National Institutes of Health Clinical Center, 9000 Rockville Pi
2021-12-30
Dec 30, 2021
N
Gemcitabine Hydrochloride, Dasatinib, and Erlotinib Hydrochloride in Treating Patients With Pancreatic Cancer That Is Metastatic or Cannot Be Removed by Surgery
Active, not recruiting
  • Metastatic Pancreatic Adenocarcinoma
  • +3 more
  • Dasatinib
  • +2 more
  • Nashville, Tennessee
    Vanderbilt University/Ingram Cancer Center
2021-12-15
Dec 15, 2021
U
Study of Dasatinib in Combination With Everolimus for Children and Young Adults With Gliomas Harboring Platelet-Derived Growth Factor Receptor (PDGFR) Alterations - 2019
Terminated
  • Glioma
  • +2 more
  • Ann Arbor, Michigan
    University of Michigan Cancer Center
2021-10-12
Oct 12, 2021
S
The Efficacy and Safety of Switching to Flumatinib Versus Dasatinib After Imatinib-related Low-grade Adverse Events in CML-CP Patients
Not yet recruiting
  • Chronic Myeloid Leukemia in Chronic Phase
  • Shenzhen, Guangdong, China
    Shenzhen Second People's Hospital
2021-06-18
Jun 18, 2021
U
Phase II Study of 5-FU, Oxaliplatin Plus Dasatinib in Metastatic Pancreatic Adenocarcinoma - 2020
Completed
Has Results
  • Pancreatic Cancer Metastatic
  • Gainesville, Florida
    UF Health Cancer Center
2020-12-03
Dec 3, 2020
N
Testing an Omega-3 Fatty Acid-Based Anti-Cancer Therapy for Patients With Inflammatory Breast Cancer That Has Spread to Other Parts of the Body
Not yet recruiting
  • Anatomic Stage IV Breast Cancer AJCC v8
  • +3 more
  • Dasatinib
  • Icosapent Ethyl
  • (no location specified)
2022-01-19
Jan 19, 2022
U
Window of Opportunity Trial of Dasatinib in Operable Triple Negative Breast Cancers With nEGFR
Active, not recruiting
  • Breast Neoplasms
  • Triple Negative Breast Neoplasms
  • Dasatinib
  • +2 more
  • Chicago, Illinois
  • +1 more
2021-10-18
Oct 18, 2021
L
Clinical Research for Azacitidine Combined With Low-dose Dasatinib in Maintenance Therapy of Acute Myeloid Leukemia
Recruiting
  • Acute Myeloid Leukemia
  • Lanzhou, Gansu, China
    The First Hospital of Lanzhou University
2021-10-07
Oct 7, 2021
M
Adding Ruxolitinib to a Combination of Dasatinib Plus Dexamethasone in Remission Induction Therapy in Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia Patients Aged 40 Years or Older
Active, not recruiting
  • Acute Lymphoblastic Leukemia
  • New York, New York
    Memorial Sloan Kettering Cancer Center
2021-07-23
Jul 23, 2021
I
Dasatinib Combined With Chemotherapy in Philadelphia Chromosome-positive Acute Lymphoblastic Leukemia
Active, not recruiting
  • Acute,Leukemia, Lymphoid
  • Dasatinib
  • +12 more
  • Tianjin, Tianjin, China
    Institute of Hematology & Blood Diseases Hospital
2021-02-08
Feb 8, 2021
C
Dasatinib and Osimertinib (AZD9291) in Advanced Non-Small Cell Lung Cancer With EGFR Mutations
Active, not recruiting
  • EGFR Gene Mutation
  • Nonsmall Cell Lung Cancer
  • Washington, District of Columbia
  • +1 more
2022-01-09
Jan 9, 2022
H
Low Dose Dasatinib (50 mg Daily) as First-line Treatment for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia
Recruiting
  • Chronic Myelogenous Leukemia
  • Dasatinib
  • Amman, Jordan
  • +4 more
2021-09-01
Sep 1, 2021
N
Testing Dasatinib as a Potential Targeted Treatment in Cancers With DDR2 Genetic Changes (MATCH-Subprotocol X)
Withdrawn
  • Advanced Lymphoma
  • +5 more
  • Dasatinib
  • Philadelphia, Pennsylvania
    ECOG-ACRIN Cancer Research Group
2020-07-17
Jul 17, 2020
N
Insulin-like Growth Factor 1 Receptor (IGF-1R) Antibody AMG479 (Ganitumab) in Combination With the Src Family Kinase (SFK) Inhibitor Dasatinib in People With Embryonal and Alveolar Rhabdomyosarcoma
Active, not recruiting
  • Rhabdomyosarcoma
  • +2 more
  • Los Angeles, California
  • +1 more
2021-11-23
Nov 23, 2021
B
Dasatinib for Immune Modulation After Donor Stem Cell Transplant for Hematologic Malignancies - 2018
Terminated
  • Non-Hodgkin's Lymphoma
  • +5 more
  • Dasatinib
  • laboratory biomarker analysis
  • Detroit, Michigan
    Barbara Ann Karmanos Cancer Institute
2020-12-14
Dec 14, 2020
B
Study of Dasatinib in Children and Adolescents With Relapsed or Refractory Leukemia - 2019
Completed
Has Results
  • Leukemia
  • Dasatinib
  • Vienna, Austria
  • +12 more
2021-02-24
Feb 24, 2021
M
Solid Tumors Using Ixabepilone and Dasatinib - 2011
Completed
  • Solid Tumor
  • Washington, District of Columbia
    Washington Cancer Institute
2020-08-03
Aug 3, 2020
F
A Study of TKI Maintenance Therapy Following Allo-HSCT in Newly Diagnosed Ph+ Adult ALL
Recruiting
  • Precursor Cell Lymphoblastic Leukemia-Lymphoma
  • +2 more
  • Dasatinib
  • Xi'an, Shaanxi, China
    First Affiliated Hospital of Xian Jiaotong University
2021-09-29
Sep 29, 2021